CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

Abstract

Aims. CD73 is a membrane associated 5′-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course. Methods. Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS). Results. High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors (n = 158) was significantly associated with longer PFS (HR: 0.228; p = 0.047) in univariable Cox regression analysis. Conclusion. High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.

Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review

“…For epithelial ovarian carcinomas, Oh et al found CD73-high expression predicted better prognosis, lower stage, and higher degree of differentiation [ 22 ]. The similar result has also been reported in nonmuscle-invasive urothelial bladder cancer [ 23 ]. Nevertheless, other researches in colorectal, gastric, gallbladder, prostate and triple negative breast cancer, proved CD73 was an unfavorable prognostic marker [ 2 , 5 , 24 , 25 ].…”

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

“…Accordingly, studies that reconcile tissue-and cell-specific roles for CD73 in normal GI tissues may help better understand CD73 in GI cancers (179,180). Similar to endometrial cancer (175), CD73 is downregulated in cancer cells of bladder and prostate tumors and associates with poor prognosis (181,182). The role of CD73 in bladder and prostate epithelium is unknown.…”

CD73s protection of epithelial integrity: Thinking beyond the barrier

“…High CD73 expression associates with lower stage and grade, less adjacent carcinoma in situ, lower proliferation index, and is a predictor of better outcome in patients with nonmuscle-invasive bladder cancer. 16 CD73 expression is associated with both good 17 and poor 7 prognosis in breast cancer. Down-regulation of CD73 in endometrial carcinoma occurs in the carcinoma cells.…”